INTERVIEW

Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President

August 14, 2017
While the Japanese generic market continues to grow on the back of the government’s push for its 80% share target, relentless pricing pressure and fierce competition are casting a shadow on the future of the industry. Me Pharma, a subsidiary…

To read the full story

Related Article

INTERVIEW

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…